Palantir Technologies Inc. - Class A Common Stock (PLTR)
173.31
+0.00 (0.00%)
NASDAQ· Last Trade: Sep 15th, 7:18 AM EDT
Detailed Quote
Previous Close
173.31
Open
-
Bid
170.50
Ask
170.80
Day's Range
N/A - N/A
52 Week Range
106.37 - 207.52
Volume
180,156
Market Cap
351.38B
PE Ratio (TTM)
279.53
EPS (TTM)
0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
28,956,129
Chart
About Palantir Technologies Inc. - Class A Common Stock (PLTR)
Palantir Technologies is a public software company that specializes in big data analytics and provides platforms for organizations to integrate, visualize, and analyze large amounts of data from disparate sources. Its flagship products, Palantir Gotham and Palantir Foundry, are designed to assist government agencies and commercial enterprises in making data-driven decisions by offering advanced analytical capabilities, collaborative tools, and visualization features. The company has gained prominence for its work with intelligence and defense organizations, as well as its growing presence in various industries such as finance, healthcare, and manufacturing, enabling clients to derive actionable insights and enhance their operational efficiency. Read More
What Happened? Shares of electronics manufacturing services provider Jabil (NYSE:JBL) fell 5.1% in the afternoon session after Goldman Sachs lowered its pric...
Arcade company Dave & Buster’s (NASDAQ:PLAY) will be announcing earnings results this Monday afternoon. Here’s what to expect. Dave & Buster's missed analyst...
Stocks fell this week on oil prices and Fed rate-hike expectations, though Oracle's earnings underscored AI infrastructure strength. MarketBeat analysts recap top stories on earnings, defense, AI, and other stock opportunities.
London, UK — Ben Harrison Raven Hung, founder of Investment Success Ben Academy Ltd , has risen to prominence as one of the youngest and most successful traders in the UK, earning a reputation for bold predictions, disciplined strategies, avoiding naysayers and remarkable returns.
Inovio Pharmaceuticals (NASDAQ:INO) said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.
President and CEO Jacqueline Shea
Palantir Technologies (NASDAQ:PLTR) used its AIPCon event to highlight customer deployments of its Foundry, Ontology and Artificial Intelligence Platform products across supply chains, aviation safety, defense manufacturing, insurance, media, pharmaceuticals and industrial operations. Speakers repea
What Happened? Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 8.5% in the afternoon session after Deutsche Bank initiated coverage on ...
Palantir won a $127 million production contract as prime contractor for the Army's TITAN ground stations, expanding its defense role even as PLTR shares pulled back after August's rally.
